GlassScriptPhysician profile
Heather Sams
NPI 1154389419
$3,701.26
in general payments reported to CMS, 2019-2025
21 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $605 · 2023: $693 · 2024: $618 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Education: $267 · Consulting Fee: $9.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.03 |
| Education | $266.52 |
| Consulting Fee | $9.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,116.42 | 2021-2025 | Andembry, Haegarda, Hizentra |
| Genzyme Corporation | $442.08 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.60 | 2021-2025 | Cuvitru, Eohilia |
| Astrazeneca Pharmaceuticals LP | $271.50 | 2022-2025 | Tezspire, Bevespi Aerosphere, Airsupra |
| Glaxosmithkline, LLC. | $250.66 | 2022-2025 | Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $223.98 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $214.77 | 2023-2025 | Dupixent |
| Pharming Healthcare, INC. | $145.83 | 2022-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $143.32 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $105.66 | 2023-2025 | Orladeyo |
| Genentech USA, INC. | $92.34 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $85.57 | 2022-2025 | |
| Pfizer INC. | $76.66 | 2021-2024 | |
| Octapharma USA, INC. | $56.53 | 2022 | |
| Grifols USA, LLC | $54.59 | 2021-2023 | Xembify |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $49.97 | 2023 | Grastek, Ragwitek, Odactra |
| Greer Laboratories, INC. | $25.52 | 2024 | Oralair |
| Ionis Pharmaceuticals, INC. | $25.23 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.02 | 2021 | |
| Cycle Pharmaceuticals INC | $11.04 | 2024 | Sajazir |
| Adma Biomanufacturing LLC | $9.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Sams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.